Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes - Wikidata - wikimedia - TriplyDB

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

http://www.wikidata.org/entity/Q33873009

about

Long-term drug treatment for obesity: a systematic and clinical review Metformin for obesity or overweight Metformin for obesity or overweight New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders Interventions to preserve beta-cell function in the management and prevention of type 2 diabetes Current and emerging medications for overweight or obesity in people with comorbidities Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide Obesity: Current and potential pharmacotherapeutics and targets.Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial Effects of exenatide in a morbidly obese patient with type 2 diabetes Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.Weight considerations in pharmacotherapy for type 2 diabetes Present and future: pharmacologic treatment of obesity Incretin-based therapies in prediabetes: Current evidence and future perspectives Prediabetes is associated with an increased risk of testosterone deficiency, independent of obesity and metabolic syndrome.Prediabetes diagnosis and treatment: A review.Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes.Preventive pharmacotherapy in type 2 diabetes mellitus.The role of incretin therapy at different stages of diabetes.Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study Effects of a 6-Month Exenatide Therapy on HbA1c and Weight in Korean Patients with Type 2 Diabetes: A Retrospective Cohort Study.Potential use of exenatide for the treatment of obesity.GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.Pharmacotherapy for childhood obesity: present and future prospects.Therapy in the early stage: incretins.Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study.A systematic review of anti-obesity medicinal plants - an update Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes.Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.Prediabetes: a high-risk state for diabetes development.A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.Molecular neuroendocrine targets for obesity therapy.Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus

P2860

Q22253010-AF09104B-17DE-419A-A6DB-54070FE664DA Q24195145-CDB8779F-0039-45E6-85D5-8ABA753CC22E Q24236796-DE223F90-0E12-477D-9736-5B4C96E23A66 Q26777654-52AFB2F0-8546-4BC1-A246-BD212E4AE6EA Q26830871-A667A497-9DAD-4531-8FEC-0B86BF022C1E Q28080825-A4A1FDC4-E4ED-4072-B080-B16D2874298B Q28081671-B93D4809-F2DD-42D1-A67A-CEB2F7FC60CE Q30243992-2FA9E2F9-71E2-440E-B123-2673B1DC0229 Q30377441-28104FD4-9D78-4845-8311-83DA9B038B97 Q33566838-EFB3138A-7C86-4526-8552-BF73B4818C1A Q33785151-D269E8FA-D872-4BD4-93B8-B13C974CC068 Q34124353-C9DA26EE-9E78-4E63-986A-33776D41C2C0 Q34159414-536B63C2-785F-4703-8B37-3754B10AF99C Q34572487-0187AE4B-04E2-44C0-B342-93579405C688 Q34699191-97B3F27D-3F5A-488F-ABBF-043AE6038449 Q34999016-F0A874D1-CC94-490D-B08E-2274BD4B6C36 Q35179236-D5BD429E-BA1E-41A3-9C9D-40DEF50B3BC3 Q35209811-BBA9E248-E648-4CE4-8F4D-41E6E7E96568 Q35620114-F20E3D01-8F0B-441A-9289-1ADEF65927E5 Q35686344-EBADBDC7-8F35-4DFD-A72D-1D698745E4D1 Q35760288-1C785768-88A2-458F-B39A-4E5814F4F8DE Q35996636-253B3863-D0B8-40A7-AF64-C54865F2BE66 Q36072493-761839B2-DCE9-4D68-A0BE-CC52A33C3CD5 Q36209444-347E7625-304E-489F-9B46-C80E930DAD6B Q36240979-89C85B5C-E319-429B-9604-2E978689AF37 Q36248001-F3F31676-2374-488B-9129-7D5AA5D132B7 Q36365237-66F04C6D-540B-4EAD-A14E-2C9ADA78CF2E Q36391466-E252F770-6EF1-4477-B541-FF1751138AAD Q36406821-1C75B2EF-9BAE-4C12-B688-388B1E845B0B Q36468087-A74D9717-5B42-41FD-A5BC-208E7817EB0A Q36783865-8829494B-3105-4513-8FBF-125D2C60BA45 Q36934365-A9986FBC-F26F-49ED-8C16-1588DF926540 Q36952394-C5636E9A-91C1-4125-99B6-F34370357F72 Q37193600-8479CFB2-893A-4433-B1C5-F102D8E33459 Q37353814-CA508D98-F331-4979-9F3A-E3427D7D58EA Q37476370-9F207CAA-7B78-421E-9648-E093A57C35DC Q37568754-92117D87-73E5-4FAD-9F82-5C8B96910216 Q37569030-716A62FD-6CCC-4817-8872-4FB6ED0D0E4A Q37580465-705E826F-2BA0-48A5-95B7-B1C69BA90E21 Q37660219-E81852D9-68A4-4789-A651-5DBEF85430BD

P2860

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

http://www.wikidata.org/entity/Q33873009

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effects of exenatide and lifes ...... with and without pre-diabetes

@ast

Effects of exenatide and lifes ...... with and without pre-diabetes

@en

type

label

Effects of exenatide and lifes ...... with and without pre-diabetes

@ast

Effects of exenatide and lifes ...... with and without pre-diabetes

@en

prefLabel

Effects of exenatide and lifes ...... with and without pre-diabetes

@ast

Effects of exenatide and lifes ...... with and without pre-diabetes

@en

P1433

Q33873009-AC7F82D1-E123-48CB-B952-40F0E710BEE5

P1476

Q33873009-9C3728AC-69FC-4040-AB4A-76A4200D147C

P2093

Q33873009-1B1EEB3A-5A7A-4998-8E97-CB2B1EEB5C94

Q33873009-1CC5392C-BB22-48A4-ABEC-2D8506338BAC

Q33873009-26B30DD2-2202-4A72-AD32-14EDC85927B9

Q33873009-619D1A7E-1734-4668-BC8E-CAA2F7B47451

Q33873009-C2510CD7-B251-492D-A83C-A130747A665C

Q33873009-CF8B4A0D-5180-46C5-A1DC-5F2538ADB91D

P2860

Q33873009-1EA6F02F-7067-413F-BD5D-6DE2429EEB7F

Q33873009-33FD8E77-DFE4-49B8-8EA0-DD6A18084E9B

Q33873009-45420F6A-2D8D-4701-8B76-F728EA1895BE

Q33873009-516A80F7-5DA3-4C45-9379-1EBF8D972D7A

Q33873009-7F83356D-B533-4D84-8A49-76B00B6AAFE9

Q33873009-833491A5-EEB1-4C61-AF26-0C19FA925363

Q33873009-9A929BD7-B488-4283-A2DE-AA6B5C738656

Q33873009-A2BDDD31-C305-4908-8161-CE463E2918FB

Q33873009-AB91C1B9-D703-4832-A3F6-94BE6EDD3357

Q33873009-BC42D564-20BB-49C1-8681-7957D762885F

P304

Q33873009-F56A99BB-0277-48C0-9058-9662098066DB

P31

Q33873009-BF2A2CF1-355D-41E3-B2F9-905503700164

P356

Q33873009-AC108DC0-EBE9-46B6-A77F-94D70DD19355

P407

Q33873009-142B5538-AF10-4011-8BAB-39E0D8FA061B

P433

Q33873009-6FF0655B-6207-410F-A6E1-7266C9BC98F4

P478

Q33873009-21BC9C49-BE04-4EDF-B6A6-F187C1921702

P50

Q33873009-E4AFEF9C-242C-43F6-8C9D-D1F166880D7A

P577

Q33873009-99F0DBDF-BAD6-40BD-9647-93DF4A14A7D8

P5875

Q33873009-F736C2D0-A38F-42BB-94CA-808A3D16BD2E

P698

Q33873009-3263AEC8-E237-4C88-A23D-9E1E35D63147

P921

Q33873009-FC68FACD-1091-4F94-866E-3335686500C8

Q33873009-f9afa9a2-6df4-42be-91e5-f86e52c90d1c

P932

Q33873009-9DE97D67-DCAC-4CF7-976B-FB190B37986C

P356

P1433

P1476

Effects of exenatide and lifes ...... with and without pre-diabetes

@en

P2093

John H Holcombe

http://www.w3.org/2001/XMLSchema#string

Justin Northrup

http://www.w3.org/2001/XMLSchema#string

Kenneth Wilhelm

http://www.w3.org/2001/XMLSchema#string

Leslie J Klaff

http://www.w3.org/2001/XMLSchema#string

Michael Trautmann

http://www.w3.org/2001/XMLSchema#string

Sherwyn Schwartz

http://www.w3.org/2001/XMLSchema#string

P2860

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.

Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.

Unraveling the science of incretin biology.

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.

P304

1173-1175

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC09-1203

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Julio Rosenstock

P577

2010-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42440759

http://www.w3.org/2001/XMLSchema#string

P698

20332357

http://www.w3.org/2001/XMLSchema#string

P921

P932

2875418

http://www.w3.org/2001/XMLSchema#string